Hycor Shares Fall After Purchase Talks End

Hycor Biomedical Inc. shares slumped after the maker of medical diagnostic products said it’s no longer in talks with potential acquirers.

The Garden Grove company’s stock, which had dipped 11 cents to $5.49 a share during regular Nasdaq trading, fell as much as $2.50 to $2.99 after hours.

The company said it’s holding discussions with other firms regarding possible product distribution arrangements, both regional and worldwide.

Hycor’s products include test kits designed to identify autoimmune diseases.